Flippin Bruce & Porter Inc. cut its holdings in Pfizer Inc. (NYSE:PFE) by 0.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 335,369 shares of the biopharmaceutical company’s stock after selling 2,988 shares during the period. Pfizer accounts for approximately 2.1% of Flippin Bruce & Porter Inc.’s portfolio, making the stock its 13th biggest holding. Flippin Bruce & Porter Inc.’s holdings in Pfizer were worth $12,050,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the company. Morgan Stanley increased its stake in Pfizer by 2.4% during the second quarter. Morgan Stanley now owns 46,536,777 shares of the biopharmaceutical company’s stock valued at $2,015,972,000 after acquiring an additional 1,071,897 shares during the period. Fisher Asset Management LLC boosted its holdings in Pfizer by 2.6% during the third quarter. Fisher Asset Management LLC now owns 45,291,398 shares of the biopharmaceutical company’s stock valued at $1,627,320,000 after purchasing an additional 1,158,147 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in Pfizer by 2,240.5% during the second quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock valued at $1,563,256,000 after purchasing an additional 34,544,423 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Pfizer by 2.5% during the second quarter. Charles Schwab Investment Management Inc. now owns 35,948,881 shares of the biopharmaceutical company’s stock valued at $1,557,306,000 after purchasing an additional 868,839 shares in the last quarter. Finally, California Public Employees Retirement System boosted its holdings in Pfizer by 5.3% during the second quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock valued at $1,004,428,000 after purchasing an additional 1,159,857 shares in the last quarter. Institutional investors and hedge funds own 71.52% of the company’s stock.
In other news, Director Scott Gottlieb acquired 3,000 shares of Pfizer stock in a transaction on Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, with a total value of $104,160.00. Following the acquisition, the director now owns 3,000 shares in the company, valued at $104,160. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Pfizer Inc acquired 50,000 shares of Pfizer stock in a transaction on Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is owned by insiders.
Shares of PFE traded up $0.14 on Friday, hitting $37.05. The company’s stock had a trading volume of 25,262,666 shares, compared to its average volume of 23,366,957. The company has a market capitalization of $207.30 billion, a PE ratio of 12.35, a PEG ratio of 2.11 and a beta of 0.67. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. Pfizer Inc. has a fifty-two week low of $33.97 and a fifty-two week high of $46.47. The company has a 50 day moving average price of $36.62 and a 200 day moving average price of $39.26.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.62 by $0.13. The business had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a return on equity of 28.61% and a net margin of 30.57%. Pfizer’s revenue was down 4.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.78 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 3.89%. The ex-dividend date is Thursday, November 7th. Pfizer’s payout ratio is currently 48.00%.
PFE has been the topic of a number of recent research reports. Morgan Stanley decreased their price objective on Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 27th. Bank of America initiated coverage on Pfizer in a report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price objective on the stock. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Finally, DZ Bank raised Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective on the stock in a report on Wednesday, August 28th. Nine analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $44.02.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: Why is cost of goods sold important?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.